Lariago-DS Tablet contains Chloroquine 500mg, an antimalarial agent primarily used for the treatment and prevention of malaria caused by Plasmodium species. Chloroquine exerts its therapeutic effect by interfering with the parasite's ability to digest hemoglobin, leading to toxic accumulation within the parasite and subsequent death. Lariago-DS is indicated for acute attacks of malaria, including uncomplicated Plasmodium falciparum and Plasmodium vivax infections, as well as for prophylaxis in endemic areas. The tablet is administered orally, with dosing adjusted according to the severity of infection and patient weight. It is essential to adhere to prescribed dosage to minimize the risk of resistance development and adverse effects. Common side effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Rare but serious adverse reactions may involve retinal toxicity, necessitating regular ophthalmologic monitoring during prolonged therapy. Caution is advised in patients with pre-existing retinal or visual field changes, hepatic or renal impairment, and in those with a history of hypersensitivity to chloroquine or related compounds. Lariago-DS should be used under medical supervision, with consideration of local resistance patterns and contraindications to ensure optimal therapeutic outcomes.